2019
DOI: 10.1111/ddg.13976
|View full text |Cite
|
Sign up to set email alerts
|

Successful treatment of sclerotic cutaneous graft‐versus‐host disease using extracorporeal photopheresis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2020
2020
2020
2020

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 15 publications
0
1
0
1
Order By: Relevance
“…Long-term immunosuppression with calcineurin inhibitors, such as cyclosporine and tacrolimus, has been associated with an increased incidence of malignancies [5,6]. These may be prevented in case of cutaneous GvHD by either phototherapy (especially PUVA or UVA1) or extracorporeal photopheresis [2,7].…”
Section: Correspondence Clinical Lettermentioning
confidence: 99%
“…Long-term immunosuppression with calcineurin inhibitors, such as cyclosporine and tacrolimus, has been associated with an increased incidence of malignancies [5,6]. These may be prevented in case of cutaneous GvHD by either phototherapy (especially PUVA or UVA1) or extracorporeal photopheresis [2,7].…”
Section: Correspondence Clinical Lettermentioning
confidence: 99%
“…La fotoaféresis extracorporéa (FEC), con una respuesta global reportada del 55-85%, o el PUVA, además de la inmunosupresión sistémica, puede mejorar la afectación fascial y prevenir las contracturas (131,132) . Además, las opciones de tratamiento para los pacientes con EICRc se han ampliado considerablemente en los últimos años, impulsadas por ensayos multicéntricos sin precedentes mediante la colaboración con la industria farmacéutica (73)(74)(75) .…”
Section: V13 Tratamiento Del Eicrc Fenotipo Escleróticounclassified